Diversity, equity, and inclusion are among the defining challenges of our time. At Eurazeo, we are committed to accelerating the shift toward a more just and cohesive society, embedding these priorities into how we invest, operate, and lead.
Accompanying Sustainable Transitions
Diversity, and inclusion are integral to our strategy for creating long-term value. We actively promote the adoption of more inclusive and fairer practices across our portfolio companies, and have implemented strict policies and ambitious targets for ourselves.
Our Exclusion Policy prevents investments in sectors or activities with negative societal impacts, as well as in companies that demonstrate unethical behavior. Investment targets are assessed for their social performance and maturity as part of the due diligence process, allowing us to identify risks and opportunities early and tailor our support accordingly.
We place particular emphasis on gender-balanced governance, advocating for equal representation on boards and in senior decision-making bodies. In countries where legal requirements are lacking, we work closely with portfolio companies to ensure essential social protection for all employees and value-sharing mechanisms.
At Eurazeo's level, we have set quantitative 2030 targets for gender diversity and equity. Beyond these objectives, we also remain committed to increasing the representation of women at all levels of our organization, particularly in investment and leadership roles. This commitment translates into tangible results: in 2025, women accounted for 47% of our workforce and 36% of our investment teams, significantly above the industry average of 24% (Level 20, European Gender Diversity Report 2024, Private Equity & Venture Capital).
Financing Solutions with a Positive Impact
We invest in companies whose products, services, or technologies offer solutions to the most pressing societal challenges, with healthcare as a cornerstone. We support the development of breakthrough therapies and the transformation of healthcare systems through digital innovation, prevention, and reindustrialization. This is reinforced by management company Kurma Partners, specializing in biotech and health tech, now entirely part of our platform. These investments are made across all our funds, covering every asset class and amount to €4.2 billion as of end-June 2026.
We also manage four healthcare impact strategies offering profitability profiles aligned with the highest standards of their asset classes:
- Nov Santé Actions Non Cotées (Private Equity – Healthcare) to reinforce the sovereignty of the European healthcare system
- Kurma Growth Opportunities Fund (Private Equity – Healthcare) to support innovative companies from biotech to health tech
- Kurma Diagnostics (Private Equity – Healthcare) to finance diagnostics, patient monitoring and digital health innovation in Europe
- Kurma Biofund (Private Equity – Healthcare) to finance new therapeutic solutions for diseases with high medical needs
